In this episode, we’re joined by Dr. James Downar, a leading Canadian voice in palliative and critical care, for a wide-ranging discussion on the emerging role of psychedelics in managing psychological and existential distress.

Psychedelics have gone from fringe to forefront in recent years, and we dig into what that shift might mean for patients facing critical illness or the end of life.

What psychedelics are and how they work

Substances like psilocybin, LSD, ketamine, and MDMA
Key effects: altered perception, ego dissolution, and emotional insight
Risks and benefits in vulnerable populations

Psychedelic-assisted therapy: structure and process

The three-phase model: preparation, the session itself, and integration
Micro dosing vs. full therapeutic sessions
Where current evidence stands

Potential applications in critical care and palliative medicine

Helping patients process fear, isolation, and suffering
How psychedelics differ from traditional symptom management tools like opioids
Limitations in advanced illness due to physiological concerns

Research and implementation challenges

Problems with study design and placebo controls
The importance of ‘set and setting’
Defining success in existential or spiritual distress

Ethical considerations and clinical integration

Balancing innovation with compassion and caution
Avoiding reductionism: why psychedelics should complement—not replace—human care
The future role of these therapies in ICU and palliative settings

Migoya responde a todo: el precio de las acciones de Globant y por qué está bullish con Milei